What is Quris Technologies?
Founded in 2020 and headquartered in Tel-Aviv, Israel, Quris Technologies operates at the intersection of artificial intelligence and biotechnology. The company has developed a sophisticated Bio-AI Clinical Prediction Platform that utilizes predictive analytics to determine the safety and viability of drug candidates before they reach human subjects. By simulating human biological responses, Quris aims to mitigate the financial and ethical risks associated with clinical trial failures, thereby streamlining the path to market for life-saving therapeutics. The firm is currently positioned as a high-growth player in the health-tech ecosystem, attracting backing from both specialized wellness funds and global technology investors.
How much funding has Quris Technologies raised?
Quris Technologies has raised a total of $9M across 1 funding round:
Angel/Seed
$9M
Angel/Seed (2022): $9M with participation from Glenrock Capital, Softbank Vision Fund, Welltech Ventures, iAngels, and Richter Group
Key Investors in Quris Technologies
Glenrock Capital
Glenrock Capital is a venture capital and private equity firm based in Dublin, Ireland, focused on identifying and supporting high-potential growth companies.
Softbank Vision Fund
SoftBank Vision Fund is a global investment vehicle that supports founders in building market-leading companies, with a specific focus on the transformative power of AI and full-stack technology ecosystems.
Welltech Ventures
WellTech Ventures is a specialized fund that invests in visionary entrepreneurs reimagining health and wellness technology through a transdisciplinary approach combining engineering and life sciences.
What's next for Quris Technologies?
With this latest injection of capital, Quris Technologies is poised to scale its operations and expand its predictive modeling capabilities. The strategic roadmap likely involves deepening partnerships with major pharmaceutical entities to integrate its AI-driven insights into existing drug development pipelines. As the company transitions from its initial development phase into a more mature operational stage, the focus will shift toward validating its platform across a broader range of therapeutic areas. Investors are closely monitoring the company's ability to translate its computational predictions into tangible clinical successes, which will be critical for long-term market leadership in the competitive AI-pharma landscape.
See full Quris Technologies company page
